P-667 Is the Turkish version of the European organisation for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) a reliable and valid measure of quality of life for patients with lung cancer treated with palliative intent?

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S260 ◽  
Author(s):  
Nalan Esrefoglu ◽  
Rachel A. Cooper ◽  
Ferhat Eyiler ◽  
Tugba Yavuzsen ◽  
Evrim Demirtas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Valid Measure ◽  
Turkish Version ◽  
European Organisation ◽  
Palliative Intent ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer

2019 ◽  
Vol 25 (8) ◽  
pp. 1853-1859 ◽  
Author(s):  
K Saranya ◽  
K Sreejith ◽  
Ajaykumar
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Normal Saline ◽  
Small Cell ◽  
Small Cell Lung ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Non-small cell lung cancer is a fatal disease associated with high morbidity. It is important to evaluate the effects of treatment on patient's quality of life. Quality of life can be assessed by using EORTC QLQ - C30 and EORTC QLQ - LC 13. Eighty-six patients were enrolled in the study. The patients were divided into four arms as follows: Patients in arm 1 received cisplatin 80 mg/m 2 and gemcitabine 1.25 g/m 2 as infusion separately in isotonic normal saline. Arm 2 received carboplatin 300 mg/m 2 and gemcitabine 1.2 mg/m 2 as infusion separately in 5% dextrose injection. Arm 3 received paclitaxel 100 mg/m 2 as infusion in isotonic normal saline and carboplatin 300 mg/m 2 as infusion in 5% dextrose injection. Arm 4 received pemetrexed 500 mg/m 2 as infusion in isotonic normal saline and carboplatin 300 mg/m 2 as infusion in 5% dextrose injection. The quality of life of the enrolled patients is based on EORTC QLQ - C30 and EORTC QLQ - LC 13 questionnaire. Prevalence of non-small cell lung cancer is more in males, 60–70 years of age. Most of the subjects were from rural areas and had only school-level education. The prevalence of non-small cell lung cancer was more with smokers, ex-smokers and patients with multiple social habits. Comorbidities also increase the risk of non-small cell lung cancer. By analyzing EORTC QLQ - C30 and EORTC QLQ - LC 13 questionnaires, it was found that diarrhea was found to be significant between the groups. Global health status and quality of life are distributed equally among each group. Quality of life and global health status are distributed equally among each sub groups.

scholarly journals The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

2021 ◽  
Author(s):  
Müge Güvençli ◽  
Enver Yalnız ◽  
Berna Kömürcüoğlu ◽  
Ahmet Emin Erbaycu ◽  
Gamze Karakurt
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Health Status ◽  
Economic Status ◽  
Social Functions ◽  
Lung Cancer Patients ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
Overall Health Status

Objective: The concept of quality of life (QoL) in lung cancer includes many physical, psychological and social components. We aimed to assess the effect of chemotherapy (CT) on QoL of lung cancer patients using QoL scales. Methods: Fifty inoperable lung cancer patients who were newly diagnosed and taken into a CT plan were included. Patients were followed in terms of responsiveness and toxicity. Turkish versions of the EORTC QLQ-C30 and LC13 scales were used before every cycles. Results: The average age was 60.1 years. There was no difference between QoL and age/income levels. The assessment of physical, social and occupational functions and overall health status of the male patients was better than female. Overall health status without comorbidity was better in the first cycle CT. Chemotherapy led to deterioration in social functions and economic status together with increase in neuropathy, constipation and hair loss. Patients with complete or partial response to treatment were observed to have better physical, occupational, emotional, cognitive and social functions, economic status and overall health; less fatigue, pain, shortness of breath, neuropathy and better appetite. Toxicities were found to affect the QLQ C30 and LC13 scales adversely. Conclusion: Presence of comorbidity, low education levels, socioeconomic status and CT induced hematologic/gastrointestinal toxicities are the major parameters affect QOL in lung cancer. Chemotherapy leads to deterioration in social functions, increase in adverse events as well as worsening in economic status. Radiologic complete or partial response and small cell carcinoma are states in which parameters of QoL are affected positively by chemotherapy.

Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7607-7607
Author(s):  
Divine Ewane Ediebah ◽  
Corneel Coens ◽  
Efstathios Zikos ◽  
Chantal Quinten ◽  
Jolie Ringash ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Performance Status ◽  
Health Related Quality ◽  
Related Quality ◽  
Eortc Qlq C30 ◽  
Health Related ◽  
Eortc Qlq ◽  
Over Time

7607 Background: Over 60 cancer clinical trials have shown that baseline health-related quality of life (HRQoL) scores are prognostic for patient survival. Few studies have investigated the added value of change in HRQoL scores. Our aim was to investigate if change in HRQoL scores from baseline over time is also associated with survival. Methods: We analyzed data from an EORTC 3-arm randomized clinical trial (RCT) in advanced non-small-cell lung cancer (NSCLC) patients, comparing gemcitabine+cisplatin, versus paclitaxel+gemcitabine, versus standard arm paclitaxel+cisplatin. HRQoL was measured in 394 patients using the EORTC QLQ-C30 at baseline and after each chemotherapy cycle. The prognostic significance of sex, age and WHO performance status (0-1 vs. 2) and the 15 QLQ-C30 subscales were assessed with Cox proportional hazard models stratified for treatment (level of significance 0.05). Changes in HRQoL scores from baseline to each chemotherapy cycle assessment were categorized as “improved”, “stable” and “worsened” using a threshold of 10 points difference. Due to expected attrition, the analysis was limited to changes from baseline up to cycle 3. Results: There were 248 patients in cycle 1, 212 in cycle 2 and 196 in cycle 3. We performed analyses separately using data at cycle 1, cycle 2, and cycle 3. In all analyses, HRQoL in various subscales and socio-demographic and clinical variables (physical functioning (hazard ratio [HR] 0.91, 95% CI 0.85-0.98; p=0.0103), pain (1.11, 1.05-1.17; p= 0.0004), age (0.98, 0.97-1.00, p=0.0413) and WHO performance status (1.77, 1.09-2.89; p=0.0218) at cycle 1; pain (1.11, 1.03-1.20; p=0.0016), age (0.98, 0.96-1.00; p=0.0217) and sex (0.63, 0.42-0.95; p=0.0081) at cycle 2; and role functioning (0.93, 0.88-1.00; p=0.0128) and age (0.98, 0.96-1.00; p=0.0081) at cycle 3) predicted survival; however, change in HRQoL was only an independent predictor for improvement at cycle 1. Conclusions: Our findings suggest that change from baseline over time in HRQoL, as measured on subscales of the EORTC QLQ-C30, contains added prognostic value for survival independent of baseline HRQoL scores. Further work is needed to assess the robustness and sensitivity of these findings.

Verbesserungen der gesundheitsbezogenen Lebensqualität durch umfassende Tumorschmerz-Therapie: Eine Pilotstudie mit ambulanten Brustkrebs-Patientinnen unter palliativer Chemotherapie

2015 ◽  
Vol 2 (1) ◽  
pp. 34-35
Keyword(s):  
Quality Of Life ◽  
Gesundheitsbezogene Lebensqualität ◽  
Life Questionnaire ◽  
Quality Of Life Questionnaire ◽  
European Organisation ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Hintergrund: Tumorassoziierte Schmerzen treten bei ambulanten Patientinnen mit metastasiertem Brustkrebs mit hoher Prävalenz auf und beeinträchtigen ihre gesundheitsbezogene Lebensqualität (gLQ). In dieser Studie wurden potenzielle Auswirkungen einer umfassenden medikamentösen Tumorschmerz-Therapie (TST) auf die gLQ untersucht.Patientinnen und Methoden: 52 ambulante Patientinnen mit metastasiertem Brustkrebs unter palliativer Chemotherapie nahmen an der Studie teil. 28 Patientinnen, die an mittelschweren bis schweren Krebsschmerzen litten, wurde eine TST angeboten. 13 dieser Patientinnen nahmen das Angebot an (Interventionsgruppe), 15 lehnten es ab (Kontrollgruppe). Die Beurteilung der gLQ erfolgte anhand des Quality of Life Questionnaire «EORTC QLQ-C30» (EORTC = European Organisation for Research and Treatment of Cancer) sowie des Brustkrebs-spezifischen Moduls «QLQ-BR23» zu Studienbeginn und nach 3 Wochen.Ergebnisse: Bei Studienbeginn klagten 83% der Patientinnen über krebsbedingte Schmerzen, wobei 35% von ihnen keine verschriebenen Schmerzmittel einnahmen. Die gLQ aller Patientinnen war im Vergleich zu den Referenz-Scores herabgesetzt. Nach der TST berichtete die Interventionsgruppe über signifikant gelinderte Schmerzen und Verbesserungen bei mehreren gLQ-Subskalen (allgemeine LQ, emotionale Funktionsfähigkeit, physische Funktionsfähigkeit, Zukunftsperspektiven, Schlaflosigkeit). Bei der Kontrollgruppe waren keine signifikanten Veränderungen zu verzeichnen.Schlussfolgerung: Diese Studie unterstreicht den Bedarf an adäquater Schmerztherapie bei palliativ behandelten ambulanten Brustkrebs-Patientinnen. Die Kombination aus TST als Richtschnur für die pharmakologische Seite des Tumorschmerz-Managements einerseits und dem «EORTC QLQ-C30» als Instrument für die Untersuchung und Überwachung andererseits erscheint als Ansatz, der weiterführende Untersuchungen verdient.Übersetzung aus Oncol Res Treat 2014;37:456-462 (DOI: 10.1159/000365537)

Is Baseline Quality of Life Useful for Predicting Survival With Hormone-Refractory Prostate Cancer? A Pooled Analysis of Three Studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group

2004 ◽  
Vol 22 (19) ◽  
pp. 3877-3885 ◽  
Author(s):  
Laurence Collette ◽  
George van Andel ◽  
Andrew Bottomley ◽  
Gosse O.N. Oosterhof ◽  
Walter Albrecht ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Prognostic Factors ◽  
Performance Status ◽  
Receiver Operating Curve ◽  
Life Questionnaire ◽  
European Organisation ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Purpose Patients with symptomatic metastatic hormone-resistant prostate cancer (HRPC) survive a median of 10 months and are often regarded as a homogeneous group. Few prognostic factors have been identified so far. We examined whether baseline health-related quality of life (HRQOL) parameters assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) were independent prognostic factors of survival and whether they bring extra precision to the predictions achievable with models based on clinical and biochemical factors only. Patients and Methods Data of 391 symptomatic (bone) metastatic HRPC patients from three randomized EORTC trials were used in multivariate Cox proportional hazards models. The significance level was set at α = .05. Results Of the 391 patients, 371 died, most of prostate cancer. Bone scan result, performance status, hemoglobin level, and insomnia and appetite loss as measured by the EORTC QLQ-C30 were independent predictors of survival. This model's area under the receiver operating curve was 0.65 compared with 0.63 without the two HRQOL factors. Conclusion Certain HRQOL sores, at baseline, seem to be predictors for duration of survival in HRPC. However, such measurements do not add to the predictive ability of models based only on clinical and biochemical factors.

Validity and reliability of the Turkish version of the functional assessment of cancer therapy–bone marrow transplant (FACT-BMT) quality of life questionnaire in patients undergoing bone marrow transplantation

2021 ◽  
pp. 1-8
Author(s):  
Vesile Yildiz Kabak ◽  
Arzu Demircioglu ◽  
Elifcan Aladag ◽  
Sevilay Karahan ◽  
Hakan Goker ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Marrow Transplant ◽  
Life Questionnaire ◽  
Turkish Version ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Abstract Objective The Functional Assessment of Cancer Therapy–Bone Marrow Transplant Version 4 (FACT-BMT) is a widely used instrument to assess quality of life in individuals treated with bone marrow transplantation (BMT). Our aim was to determine the reliability and validity of the Turkish version of the FACT-BMT in patients undergoing BMT. Method Patients between the age of 20 and 65 years and who had undergone BMT at least 3 months before the study were included. Validity was determined using exploratory and confirmatory factor analysis. To determine convergent validity, the European Cancer Research and Treatment Organization Quality of Life Questionnaire–Cancer30 (EORTC QLQ-C30), the Brief Fatigue Inventory (BFI), and the Eastern Cooperative Oncology Group (ECOG) performance score were used. Cronbach's alpha, intra-class correlation coefficient (ICC), and item-total correlation (ITC) values were calculated to assess the reliability of the FACT-BMT. Results Totally, 114 patients (F/M: 47/67) treated with BMT (mean age: 49.50 ± 12.50 years) were included. Confirmatory and exploratory factor analysis revealed that the FACT-BMT and the Bone Marrow Transplantation Subscale (BMTS) had sufficient fit. The FACT-BMT was moderately to strongly correlated with the EORTC QLQ-C30, the BFI, and the ECOG performance score (p < 0.001). Cronbach's alpha and ICC values of the FACT-BMT were acceptable (0.925 and 0.956, respectively). The ITC values of each item of the FACT-BMT were also acceptable (ranged from 0.296 to 0.737). Patients undergoing autologous BMT had a significantly higher BMTS score than those undergoing allogeneic BMT (p < 0.05). Significance of results The Turkish version of the FACT-BMT is valid, reliable, and sensitive to changes in quality of life in patients undergoing BMT.

Sign in / Sign up

Export Citation Format

Share Document